Biopharmaceutical company Alvotech Holdings SA said on Tuesday it plans to list in New York by merging with a blank-check company backed by Oaktree Capital Management, in a deal that values the combined entity at around $2.25 billion.
The Iceland-based company will receive gross proceeds of $450 million from the deal, including $150 million from a private placement in public equity backed by Temasek, CVC Capital Partners and funds managed by Suvretta Capital among others.
Oaktree Acquisition Corp II, a special purpose acquisition company (SPAC), raised $225 million through an initial public offering (IPO) in September last year.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.